Product news

Share this article:
The FDA has broadened the US indication for Novartis' Reclast (zoledronic acid) once-yearly injection to include the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture. The FDA decision is based on safety and efficacy data from the “Recurrent Fracture Trial,” published in The New England Journal of Medicine. Trial results showed a 35% reduction in the risk of new clinical fractures in patients treated with Reclast, Novartis said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.